Could an antibody drug tame psoriasis and heart risk at once?
NCT ID NCT04776629
First seen May 19, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This study tested a drug called orticumab in 77 adults with moderate-to-severe psoriasis who also had extra heart and metabolic risks (like obesity and high cholesterol). The goal was to see if the drug could safely improve skin symptoms and possibly lower inflammation tied to heart disease. Participants received either orticumab or a placebo, and researchers tracked changes in psoriasis severity and other health markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Blue Coast Research Center
Vista, California, 92083, United States
-
CCT Research - Springville Dermatology
Springville, Utah, 84663, United States
-
CCT- Research at the center for Dermatology and Plastic Surgery
Scottsdale, Arizona, 85260, United States
-
Center for Clinical Studies, LTD.LLP
Webster, Texas, 77598, United States
-
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, 46250, United States
-
Derm Institute & Skin Care Ctr., Inc.
Santa Monica, California, 90404, United States
-
Excel Clinical Research
Las Vegas, Nevada, 89109, United States
-
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
-
Las Vegas Clinical Trials
Las Vegas, Nevada, 89030, United States
-
Orange County Research Center
Tustin, California, 92780, United States
-
SMS Clinical Research
Mesquite, Texas, 75149, United States
-
Texas Dermatology and Laser Specialists
San Antonio, Texas, 78218, United States
-
Vital Prospects Clinical Research Institute, PC
Tulsa, Oklahoma, 85260, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
orticumab (a lab-made antibody targeting oxidized LDL)
What this could lead to
If it works, this could point toward a treatment that helps both psoriasis and related heart disease risks.
What could go wrong
This is a small, early-phase proof-of-activity study, so results may not be conclusive. The drug may not improve psoriasis or heart risk, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.